Cited by 108Metabolism and Genetic DisordersNeurological diseases and metabolismMitochondrial Function and Pathology

Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: A paradigm for multifactorial neurodegenerative diseases?

Open access
Galea, Elena, Launay, Nathalie, Portero-Otin, Manuel, Ruiz, Montserrat, Pamplona, Reinald, Aubourg, Patrick, Ferrer, Isidre, Pujol, Aurora·2012·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Abstract

X-linked adrenoleukodystrophy (X-ALD) is an inherited neurodegenerative disorder expressed as four disease variants characterized by adrenal insufficiency and graded damage in the nervous system. X-ALD is caused by a loss of function of the peroxisomal ABCD1 fatty-acid transporter, resulting in the accumulation of very long chain fatty acids (VLCFA) in the organs and plasma, which have potentially toxic effects in CNS and adrenal glands. We have recently shown that treatment with a combination of antioxidants containing α-tocopherol, N-acetyl-cysteine and α-lipoic acid reversed oxidative damage and energetic failure, together with the axonal degeneration and locomotor impairment displayed by Abcd1 null mice, the animal model of X-ALD. This is the first direct demonstration that oxidative stress, which is a hallmark not only of X-ALD, but also of other neurodegenerative processes, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), contributes to axonal damage. The purpose of this review is, first, to discuss the molecular and cellular underpinnings of VLCFA-induced oxidative stress, and how it interacts with energy metabolism and/or inflammation to generate a complex syndrome wherein multiple factors are contributing. Particular attention will be paid to the dysregulation of redox homeostasis by the interplay between peroxisomes and mitochondria. Second, we will extend this analysis to the aforementioned neurodegenerative diseases with the aim of defining differences as well as the existence of a core pathogenic mechanism that would justify the exchange of therapeutic opportunities among these pathologies.

Integrity signals

Registry

Crossref · 10.1016/j.bbadis.2012.02.005

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In many neurodegenerative diseases, including AMN, axonal pathology precedes cell body loss in the form of dying back axonopathy.

    “In many neurodegenerative diseases, including AMN [49,89,181,187,288,294,295,296,297], axonal pathology precedes cell body loss in the form of “dying back axonopathy”, in which axons gradually degenerate toward the cell body [298,299].”

    From Revisiting the Pathogenesis of X-Linked Adrenoleukodystrophy (2025) · cites this paper as [187]

The citation lists haven’t been fetched yet

References 184 · Cited by 108

Authors
Galea, E., Launay, N., Portero-Otin, M., Ruiz, M., Pamplona, R., Aubourg, P., Ferrer, I., & Pujol, A.
Affiliations
  • Institució Catalana de Recerca i Estudis Avançats (ES)
  • Instituto de Salud Carlos III (ES)
  • Universitat de Lleida (ES)
  • Inserm (FR)
Corresponding author
Pujol, Aurora
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Publisher
Elsevier BV
Published
2012-09
Volume
1822
Issue
9
Pages
1475-1488
ISSN
0925-4439 (ISSN-L)
OpenAlex
W2006135287
Cited by
108
References
184
Citations by year
2026: 1 · 2025: 2 · 2024: 8 · 2023: 3 · 2022: 12 · 2021: 6 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 8 · 2016: 9 · 2015: 18 · 2014: 8 · 2013: 18 · 2012: 5
FWCI
1.90
Type
journal article
Language
en
Open access
Locations
  • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Repositori ObertUDL (University of Lleida) (publishedVersion)
  • RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion)
Funders
  • European Commission (FP7-241622)
  • European Leukodystrophy Association (ELA2009-041D6, ELA2008-040C4)
  • Oliver's Army
  • Spanish Institute for Health Carlos III (FIS PI080991)
  • Autonomous Government of Catalonia (2009SGR85, 2009SGR735)
  • Spanish Ministry of Science and Innovation (BFU2009-11879/BFI)
  • Spanish Ministry of Health (PI081843, PI0111532)
  • ‘La Caixa’ Foundation
  • COST B35 Action of the European Union
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords
X-linked adrenoleukodystrophy, oxidative stress, axonal degeneration, very long chain fatty acids, peroxisomes, mitochondria, redox homeostasis, energy metabolism, inflammation, antioxidants, alpha-tocopherol, N-acetylcysteine, alpha-lipoic acid, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, translational therapy
MeSH terms
Adrenoleukodystrophy, Animals, Antioxidants, Axons, Cell Membrane, Humans, Inflammation, Mitochondria, Reactive Oxygen Species, Oxidative Stress, Neurodegenerative Diseases, Peroxisomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review